Genedrive file US FDA Pre-Submission for the Genedrive ® MT-RNR1 Product Range
Genedrive file US FDA Pre-Submission for the Genedrive ® MT-RNR1 Product Range
genedrive plc (AIM: GDR), the near-patient molecular diagnostics company, announces that the UK’s National Institute for Health and Clinical Excellence (‘NICE’) has commenced an evaluation of CYP2C19 genotype testing for
Purchase of 10m Abingdon Health Simply Test COVID-19 antigen tests; subject to Taiwan FDA approval of test
genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that the UK Medicines and Healthcare Products Regulatory Agency has granted a CTDA enabling the sale of the Genedrive®
York, U.K. 30 May 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, announces that it has signed a Testing
Significant contract signed to manufacture lateral flow device components
Focused on the on development and commercialisation of Lyme disease lateral flow self-test
Completion of Technical Transfer to full-scale manufacture and initial orders for Vatic KnowNowTM test
NICE issues Medtech Innovation Briefing on Genedrive ® MT-RNR1 Test
World’s first point of care genetic test used to influence neonatal management in an acute setting and reduce aminoglycoside-induced hearing loss​​
First NHS Deployments of the Genedrive® System for Antibiotic Induced Hearing Loss